Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 May 2021 | Story Xolisa Mnukwa
The 2021 Kovsie ACT Eco-vehicle race puts students’ sustainable energy and critical thinking skills to the test.

The University of the Free State (UFS) Division of Student Affairs’ (DSA) Director of Student Life, Dr WP Wahl, believes the knowledge and skills that students have gained through participating in the 2021 Eco-vehicle project will position them more optimally in the future world of work. “We are also tremendously grateful for the project funding received from merSETA; without their support, none of this would have been possible,” he remarked.

The Kovsie ACT Eco-vehicle race, in conjunction with the overall programme, was established to encourage students to learn more about the technology and logic behind sustainable energy sources and how this can influence the future global society.

This year’s events witnessed students competing according to their UFS residence teams, with Sonnedou, Legatum, Kestell (SonLeTell); Soetdoring, Beyers Naude, Arista (Soetbeyrista); and Roosmaryn, Kagiso, Karee (Kar-is-myn) ending in first, second, and third place respectively, obtaining the highest scores for the races they competed in.

Anton Calitz, Electrical Engineer in University Estates who was the announcer on the day, described the event as one that exceeded his wildest expectations. “From a sustainable energy point of view, the eco-vehicle race results really turned the tables, with lower energy usage per lap being successfully recorded – as anticipated,” he further added.

Andre van Wyk, Client Liaison Officer of merSETA (Manufacturing, Engineering and Related Services Seta) for the Free State and Northern Cape – as one of the sponsors of the innovative programme – extended warm congratulations to the UFS for hosting an outstanding event. He further applauded the university for its resourcefulness in virtually adding electronic media broadcasts to extend the event to the entire UFS community.

“The Kovsie ACT Eco-vehicle programme was eye-opening and exposed me to the broad field of electronics. It definitely came as a challenge – one I had not anticipated on that level, because at times I couldn’t even see what all the building was leading to, but I just had to put my mind and hands to work – it pushed me to think critically and creatively. I was honoured to have been part of this entire experience and I’m grateful to Anton and his team, as well as the Kovsie ACT office, for being a constant support structure throughout the process, as it was not easy.” 

These were the humble words of Sinegugu Sibisi, a University of the Free State (UFS) student who was part of the 2021 Kovsie ACT Eco-vehicle race, where sustainable energy was at the order of the day.

For more information about the Kovsie ACT eco-vehicle skills programme, email ACT at ACT@ufs.ac.za
 

 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept